Just last week, Celgene Corp.'s head of business development, George Golumbeski, told a packed breakout session at the annual J.P. Morgan Healthcare Conference in San Francisco that the firm's long-term pipeline "can never be big enough."
Depomed Inc. said it expects its annual revenue to more than double in 2015 with the addition of U.S. rights to Janssen Pharmaceuticals Inc.'s Nucynta pain drug franchise.
SAN FRANCISCO – It's been a big week for billionaire physician and biotech veteran Patrick Soon-Shiong. He was awarded two separate presentation slots at the J.P. Morgan Healthcare Conference and his ambitious holding company Nantworks LLC launched new start-up venture Nantcell LLC, an immuno-oncology firm that began by licensing a late-stage monoclonal antibody from Amgen Inc.
SAN FRANCISCO – Opening his presentation during the J.P. Morgan Healthcare Conference Wednesday morning, Hospira Inc. CEO Michael Ball zipped through updates on the firm's injectable and device businesses and focused the majority of his talk on the firm's efforts in biosimilars, a space that finally appears to be opening up in the U.S.
SAN FRANCISCO – Shares of Pharmacyclics Inc. jumped 11.4 percent in afterhours trading Monday following a lively afternoon presentation during which the Sunnyvale, Calif.-based firm told attendees of the J.P. Morgan Healthcare Conference that it expected cancer drug Imbruvica (ibrutinib) to hit blockbuster status in 2015.
SAN FRANCISCO – Celgene Corp. kicked off the J.P. Morgan Healthcare Conference Monday morning with a long-term financial outlook that combines the firm's tradition of conservative guidance, while placing emphasis on growing sales of top-selling drug Revlimid (lenalidomide) and a host of promising partnered programs, all with the projection of nearly tripling sales numbers by the year 2020.
A year after anti-GM-CSF monoclonal antibody KB003 failed in a phase II severe asthma study, Kalobios Pharmaceuticals Inc. once again found itself shifting priorities on news of the phase II miss for its second lead product, anti-PcrV monoclonal antibody fragment KB001-A, in treating Pseudomonas aeruginosa (Pa) lung infections in cystic fibrosis (CF) patients.
Amgen Inc. is bolstering its immuno-oncology franchise and making its first foray into the hot chimeric antigen receptor (CAR) T-cell therapy field through an early stage deal with Kite Pharma Inc. that, if successful, could prove lucrative for both firms.
In the days leading up to Christmas, the FDA seemed to get into the holiday spirit, bestowing a flurry of drug approvals and bringing the total number of 2014 nods to 41 – with still one week to go – solidly topping the total of 27 drugs that got approved in 2013.
Analysts may have to wait for detailed data to be presented at an upcoming medical meeting to tease out the market potential for Radius Health Inc.'s subcutaneous abaloparatide in postmenopausal osteoporosis, but the good news is that the Waltham, Mass.-based company's synthetic peptide analogue of human parathyroid hormone-related protein solidly hit its primary endpoint in a phase III trial.
